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Abstract
Background: When evaluating health technologies with insufficient scientific evidence, only innovative potentials
can be assessed. A Regional policy initiative linking the governance of health innovations to the development of
clinical research has been launched by the Region of Emilia Romagna Healthcare Authority. This program, aimed at
enhancing the research capacity of health organizations, encourages the development of adoption plans that
combine use in clinical practice along with experimental use producing better knowledge. Following the launch of
this program we developed and propose a method that, by evaluating and ranking scientific uncertainty, identifies
the moment (during the stages of the technology’s development) where it would be sensible to invest in research
resources and capacity to further its evaluation. The method was developed and tested during a research project
evaluating robotic surgery.
Methods: A multidisciplinary panel carried out a 5-step evaluation process: 1) definition of the technology’s
evidence profile and of all relevant clinical outcomes; 2) systematic review of scientific literature and outline of the
uncertainty profile differentiating research results into steady, plausible, uncertain and unknown results; 3) definition
of the acceptable level of uncertainty for investing research resources; 4) analysis of local context; 5) identification
of clinical indications with promising clinical return.
Results: Outputs for each step of the evaluation process are: 1) evidence profile of the technology and systematic
review; 2) uncertainty profile for each clinical indication; 3) exclusion of clinical indications not fulfilling the criteria
of maximum acceptable risk; 4) mapping of local context; 5) recommendations for research.
Outputs of the evaluation process for robotic surgery are described in the paper.
Conclusions: This method attempts to rank levels of uncertainty in order to distinguish promising from hazardous
clinical use and to outline a research course of action. Decision makers wishing to tie coverage policies to the
development of scientific evidence could find this method a useful aid to the governance of innovations.
Background
Innovations pose serious challenges to Health Systems
committed to delivering effective and updated health
care, while resisting the pressures of unremitting moder-
nization [1]. A significant number of technologies
become available with a limited knowledge base and
well before their process of evaluation is completed [2].
Decision makers have to choose between early, perhaps
hazardous, adoption and delay or time-buying while
further scientific evidence is being produced. Both deci-
sions carry their own share of risk: the first decision
may lead to the spread of ineffective or even harmful
care, as well as unnecessary costs; the second one may
cause denial of (later-proven) effective care.
The pressure to innovate and the length of time
necessary for the publication of robust results make it
difficult to “freeze” decisions and health organizations
need criteria to discriminate really promising innova-
t i o n sf r o ml e s sa d v a n t a g e o u so n e s .M o r e o v e rp a s t
experiences tell us that early adoption often proves to
be a “research killer”:t h ed r i v ea n dt h ee c o n o m i c
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any medium, provided the original work is properly cited.interests for the collection of further evidence diminish
once the new technologies have entered clinical practice,
while the ethical problems related to the recruitment
and randomization of patients increase [3].
Policy options - such as Coverage with Evidence Devel-
opment (CED) or Only in Research options (OIR) -
adopted by Medicare in the US, NICE in the UK and
other European institutions, try to combine early use in
clinical practice with the development of the further
research needed [3-6]. Even with these options at hand,
which do not guarantee resolution of all uncertainties,
the investment remains substantial and requires a bal-
ance between the risk of immature investment and the
benefit of diminishing uncertainty. Tools have therefore
been developed, such as the Value of Information analy-
sis, to assess the need for further research and its poten-
tial advantages [7].
If further research can inform decisions on the adop-
tion of new technologies, formulating the relevant and
useful research questions is a crucial step for the success
of the effort. Within a governmental programme,
launched by our Region, the governance of innovations
has been linked to the development of the research
capacity of the Region’s Health Trusts and Hospitals.
These are encouraged, when proposing adoption of
innovative technologies, to outline research projects
addressing some of the unresolved questions. At present
the programme does not involve coverage schemes for
new technologies linked to the production of evidence,
and decisions on acquisition and adoption are left to the
local Health Trusts, provided they take on responsibility
for prospective evaluations of the claimed clinical bene-
fits. A substantial Regional grant has been allocated to
health and clinical research and professional networks
adopting new technologies are invited to submit
research proposals to obtain funding.
A Regional Observatory for Innovation (ORI) has
been set up by the Regional Agency for Health and
Social Care (ASSR-RER) to support decision-makers
and health professionals in carrying out evaluations of
technological and clinical organisational innovations,
both retrospectively, through systematic reviews and
appraisal of evidence, and prospectively through clini-
cal trials.
To implement this long-term research programme
ORI has developed a method for the evaluation of new
technologies, aimed at supporting professionals and
managers in their preliminarily assessment of technolo-
gies and in formulating research proposals. This method
involves assessing and ranking the scientific uncertainty
surrounding a new technology and identifying the point
in time, during the development of the technology,
where it would be wise to invest research resources and
capacity to further its evaluation.
We propose this method, piloted within a HTA
project on robotic assisted surgery, which involves:
- the outline of an uncertainty profile of the technol-
ogy, based on the systematic review of the literature,
- the development of a research programme strategy
based on the knowledge needs expressed by experts and
stakeholders.
The ultimate goal of this process is to advise on
research initiatives necessary to fill existing knowledge
gaps and not to recommend options and behaviour for
routine clinical practice.
Objective
To asses the stage of the evaluation process of an inno-
vative health technology, identify research gaps and
prioritise research questions.
Context
Robotic-assisted surgery is a form of minimally invasive
surgery carried out with a device that comprises the fol-
lowing components: computer console, patient-side cart
and detachable instruments. The surgeon is situated at
the console, several feet away from the operating table,
and operates instruments attached to multiple robot
arms. The robotic arms are attached to the operating
table and perform the surgeon’s movements translated
by the computer on the patient. This robotic system
provides three-dimensional visualization, intuitive move-
ment of instruments, and 360° manoeuvrability of the
tips of the instruments through the laparoscopic ports.
Surgical robots are a highly expensive technology
(around Euro1.8 - 2 million) and have already been
introduced in two district hospitals in the Emilia-
Romagna Region via donations from non-profit organi-
z a t i o n s .T h ei n i t i a lc o s t sw e r en o ts u s t a i n e db yt h e
Regional Health System but the very high costs of use
and maintenance bear down on public resources. In
order to ensure safe and appropriate clinical use of the
robot and to capitalize on this technology ORI under-
took an evaluation [8]. Although Regional Health Trusts
and Hospitals enjoy a fair degree of autonomy regarding
acquisition and use of health technologies, the Regional
Health Authority deemed it necessary to slow further
diffusion of surgical robots and issued an official notice
asking the general managers of the hospitals to restrain
from acquiring more surgical robots and from accepting
further donations until completion of the formal evalua-
tion undertaken by ORI.
Methods
The proposed method is built on a number of proposi-
tions. The first proposition is that, before starting an
evaluation process, a strong theoretical case should be
made for a new technology, stating the rationale for its
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cal clinical and health benefits that would make its use
worthwhile. The second proposition is that the available
evidence should be evaluated against this blue print of
conceptual clinical effectiveness, leading to an uncer-
tainty profile of the technology, which is used to high-
light knowledge gaps. The third proposition is that,
following the theoretical rationale for the technology
and the appraisal of the evidence, a critical outcome or
dimension is identified to determine the stage of devel-
opment of the technology. The final proposition is that
the research questions developed through the preceding
exercise should be prioritised according to the research
capacity of the local context.
a) The theoretical rationale
Immature technologies still in the process of having
their clinical place and relevance defined, are often pro-
posed for a variety of clinical indications and the litera-
ture reports a large array of patients, diseases and
outcomes [9]. It is therefore necessary to clarify the
innovative elements of the technology and its potentials.
Starting from the technical characteristics of the tech-
nology, a theoretical rationale for its clinical effective-
ness is defined and an evidence profile is mapped to
outline the research questions aimed at proving the the-
oretical rationale. All relevant outcomes related to tech-
nical performance, feasibility, safety, clinical effectiveness
and cost-effectiveness are specified.
The decision to define relevant outcomes before
analysing the scientific literature is based on the rea-
soning presented by the GRADE group, an interna-
tional collaboration that has researched and proposed
a method for the development of recommendations
for clinical practice [10]. This method, discussed, cri-
tiqued and adopted by several guideline agencies, aims
at a transparent process for the appraisal of evidence
and the weighing up of benefits and risks of health
interventions. It is claimed that discussion and agree-
ment upon relevant outcomes, prior to reviewing the
scientific literature, ensures that evaluation of the
published research and subsequent development of
recommendations are made explicit and unbiased by
the search results. As literature on immature technol-
ogies is often limited to feasibility and safety out-
comes, the initial experts’ input for the definition of
outcomes related to clinical effectiveness proves
indispensable.
b) The uncertainty profile
Immature technologies are commonly supported by a
low quality body of evidence (i.e. case series and
uncontrolled studies) unsuitable to draw any firm con-
clusions from. Despite this, it is still possible to
explore this uncertainty. Following the traditional line
of development and evaluation of a new technology -
from technical performance to cost-effectiveness [11] -
the Regional Observatory for Innovations developed a
system for grading levels of uncertainty. The principle
used to differentiate between levels of uncertainty is an
adaptation of the grading of the level of evidence
developed by the GRADE group. The GRADE’s
method for the development of recommendations for
clinical practice involves assessment of both the level
of evidence and of the strength of each recommenda-
tion. Quality and level of evidence is classified and
graded according to whether “further research is [more
or less] likely to change the level of confidence in the
estimate of effect” [12]. In order to evaluate and cate-
gorize evidence drawn from low quality studies, we
analysed results according to the likelihood that further
studies and of better methodological quality would
change size and direction of estimates.U s i n gt h i s
adapted criterion, the resultso ft h es t u d i e sa r ec l a s s i -
fied into the following four categories:
1. Steady results: results that are highly unlikely to
be changed by further studies
2. Plausible results: consistent results coming from
sufficiently numerous high quality observational stu-
dies and related to outcomes for which comparative
evaluations are not strictly necessary
3. Uncertain results: results that would most prob-
ably change, in both size and direction of estimate, if
evaluated through randomised clinical trials
4. Unknown results: unreported /non-existent
results on outcomes judged by the panel to be rele-
vant for the evaluation of the technology
Full definitions and examples for the four categories
are provided in Table 1.
This evaluation of the evidence - similar to an “evi-
dence mapping” exercise [13] - is carried out for each
clinical use and provides an uncertainty profile of the
technology for the different indications taken into
examination
c) Identification of the critical outcome/dimension
Within the research and evaluation continuum (pro-
ceeding from technical performance, feasibility, safety,
clinical effectiveness to cost-effectiveness) the critical
outcome within the critical domain is chosen as the
boundary for judging the technology to be ready for eva-
luation through Phase III clinical trials. At least plausi-
ble results are deemed essential for this critical outcome.
This imaginary line, which identifies the technology’s
stage of development at which it is sensible for a health
service to invest research resources, sets the boundaries
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types of risk boundary would be set for different tech-
nologies, depending on their purpose, function and clin-
ical rationale.
d) Assessment of research capacity of the context
Once a list of clinical indications and relating research
questions is drawn up, priority for research proposals is
decided using the following criteria:
- existing high-profile professional expertise and
institutes of excellence capable of employing and
evaluating the technology through appropriate
research programmes;
- adequate estimated size of the target population for
the intended clinical use, for which a plausible bene-
ficial clinical impact is expected.
The proposed method, based on the above assump-
tions, is applied in a five step process (Figure 1) carried
out by a multidisciplinary panel of experts. Outputs of
each phase of the process used to evaluate the Da Vinci
robot are described below.
Results
Step 1 - Technical description of the technology,
definition of the theoretical rationale in favour of the
technology and list of relevant clinical outcomes
A comprehensive description and assessment of the
technical characteristics of the technology was prepared
by the clinical engineers. Scope of this effort was to pro-
vide the working group with an adequate background of
information to understand and appreciate the function-
ing of the technology, differences from existing similar
technologies and advantages and improvement on tech-
nical performance. This information was also used to
define the appropriate comparators.
A multidisciplinary panelo fe x p e r t sw a sc o n v e n e d
consisting of clinicians, clinical engineers, methodolo-
gists, epidemiologists, health economists, hospital
administrators and other stakeholders. Surgeons “in
favour” and surgeons “against” robotic assisted surgery
were invited. The panel defined the theoretical rationale
in favour of the new technology as follows: robotic
assisted surgery is a form of minimally invasive surgical
technique that could prove more effective than others,
due to its greater precision in performing demolishing
Table 1 Process of Evaluation of Immature Technology: categorisation of published research results
Level of uncertainty Description
Steady results :
results that are highly unlikely to be changed by further studies.
Results derived from well conducted comparative trials, i.e. systematic
reviews of randomised controlled trials, several randomized controlled
trials or quasi randomised trials or controlled non randomised studies with
adequate adjusting for confounding factors, large sample sizes and
concordant statistically significant results.
Example of Da Vinci robot: steady results limited to absolute costs
Plausible results:
consistent results, coming from sufficiently numerous observational
studies, which would probably not change significantly if evaluated
through randomised clinical trials.
a) consistent results derived from high quality observational studies (i.e.
prospective comparative cohort studies with adequate adjusting for
confounding factors) showing remarkable results for real benefits unlikely
to be changed for direction of estimate by further randomised trials;
b)consistent results related to outcomes that do not demand evaluation
through comparative studies, as judgements are based on performance
against absolute values or thresholds and the new technology is not
required to perform better than the current alternatives.
Example of Da Vinci robot: plausibly stable results of a robotic-assisted
surgical intervention related, for feasibility, to results showing duration of
intervention consistently keeping below maximum-time duration threshold
and, for safety, to results consistently showing keeping below a maximum
quantity of blood-loss threshold
Uncertain results:
results that would most probably change, in both size and direction of
estimate, if evaluated through randomised clinical trials.
Results coming from uncontrolled studies related to outcomes that need
rigorous comparative studies, as their evaluation relies on differences
between estimates and because the new technology is required to
perform differently from the current alternatives.
Example of the Da Vinci robot: uncertain results related to surgical outcomes
(i.e. adequate margins) and secondary clinical outcomes (such as continence,
sexual potency for prostatectomy, time to nutrition for gastrointestinal
surgery)
Unknown results Unreported or non-existent results on all outcomes judged by the panel
to be relevant for the evaluation of the technology.
Example of the Da Vinci robot: unknown results related to outcomes such as
disease-free time, recurrence, survival, mortality etc. not assessed by any of
the published studies
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small sites, leading to presumably better surgical out-
comes, less adverse effects and equivalent primary clini-
cal outcomes.
The appropriate comparator for robotic surgery was
therefore identified in other laparoscopic surgery techni-
ques. The relevant outcomes for evaluating feasibility
were chosen to be the duration of the intervention,
costs, conversion to open or other laparoscopic surgery
and the learning curve, while safety was assessed in
terms of blood loss, need for transfusion, intra and post-
operative complications. The evaluation of efficacy was
decided to be based on surgical outcomes and secondary
and primary clinical outcomes. In the example of the
use of the Da Vinci robot for radical prostatectomy the
panel defined the target population (patients diagnosed
with prostate cancer in stage < = T2 eligible for radical
surgery); the expected benefits (less adverse effects and
equivalent clinical effectiveness); the relevant clinical
outcomes (continence, sexual potency, adequate surgical
margins, biochemical failure and survival).
The panel decided on the critical outcome/domain
and set the cut-off line at the safety stage, agreeing that
clinical indications lacking plausible results on safety
would be excluded from the list of locally researchable
questions
Step 2 - Uncertainty profile: systematic review of the
scientific literature, ranking of uncertainty and mapping
of the stage of knowledge
The systematic review and appraisal of published studies
was developed in two phases. An initial systematic
search and appraisal of all published HTA reports,
guidelines, systematic reviews and meta-analysis was
carried out to obtain a good overview of all evaluated
clinical uses. The initial systematic review of the litera-
ture review on robotic surgery produced a fairly long
list of surgical interventions in which robots had been
tested, ranging from very simple (cholecystectomy) to
more complex ones (cardio-thoracic surgery, paediatric
surgery).
The results of the review were presented to the panel
and members were asked to identify the clinical indica-
tions of greatest interest considering the following: the
clinical rationale o ft h et e c h n o l o g y ,t h ev o l u m ea n d
quality of existing literature for each clinical indication
and the context capacity to “accommodate” the technol-
ogy’sc l i n i c a lu s e .O nt h eb a s i so ft h e s et h ep a n e l
decided that the second phase of systematic reviews of
all primary studies should be carried out on the use of
the Da Vinci robot in urological, abdominal, gynaecolo-
gical, bariatric and thoracic surgery. The specificity of
the local context thus did impact on the subsequent
research questions and content of the report as indica-
tions such as heart surgery were excluded, due to the
absence of local expertise in minimally invasive surgery
in this field. This is justified by the fact that any future
investment must be linked to and based on the real
potentials of use offered by the context hosting the new
technology. A further systematic review of all published
primary studies was then carried out on this subsection
of clinical indications. All retrieved studies were assessed
and synthesised in tables of evidence reporting study
design, number of patients, comparators and estimates
for outcomes.
Results of the studies were then graded according to
the different levels of uncertainty, providing an
Figure 1 Process for the Evaluation of Immature Technology.
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indication taken into examination (see example in
Figure 2).
The value of this exercise was manifold:
- It allowed the stage of development of the technol-
ogy to be charted on the research continuum and to
compare stages reached by different clinical
indications.
-I tp r o v i d e dab l u ep r i n tf o rf u t u r er e s e a r c h
questions.
- It provided the parameters for future updating of
the literature review.
Step 3: Exclusion of clinical indications
On the basis of the uncertainty profile the panel decided
which clinical indications of the technology were to be
Figure 2 Uncertainty Mapping: example of the Da Vinci robot.
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exclusion criteria were applied.
T h ef i r s to n ew a sd e t e r m i n e db yt h ec u t - o f fl i n ef o r
the acceptable maximum risk, set by the panel at the
safety dimension, which consented the exclusion of the
clinical indications with no plausible results on safety
outcomes (blood loss, intra-operative complications,
conversion to open surgery etc.). The concept of plausi-
bility helped to deal with uncertainty and discriminate
potentially promising from hazardous use of a technol-
ogy. (i.e. gastrectomy, lobectomy, esophagectomy etc.).
The second criterion for exclusion was based on the
importance attributed to the clinical outcomes: indica-
tions were excluded when the presumed better perfor-
mance of the technology was related to clinical
outcomes judged by the panel to be of limited impor-
tance. Further clinical indications were thus excluded by
the panel (for example cholecystectomy) as the pre-
sumed advantages over laparoscopic surgery were con-
sidered of insufficient clinical value.
While the exclusion based on the lack of plausible
results is guided by the analysis of the literature, the
exclusion based on the importance of the outcomes
implies a value judgement expressed by the panel at the
outset of the process.
Step 3 concluded with a list of clinical indications for
which the technology was considered ready to be evalu-
ated through comparative effectiveness trials (radical
prostatectomy, colectomy, hysterectomy, fundoplication,
bariatric surgery, thymectomy). The remaining indica-
tions were excluded because in need of further trials
evaluating safety or because suggesting minor clinical
benefit.
Step 4: prioritisation of clinical indications relevant for the
local context
The range of clinical indications was further narrowed
down using characteristics of context as criteria for the
prioritisation of relevant clinical questions.
Output of step four was a context mapping aimed at
evaluating the presumed clinical impact of the technol-
ogy on the local health system. Regional data reports on
patients undergoing the different surgical procedures, for
which robotic surgery showed important potentials, were
produced, as well as reports on volumes of activity and
performance of all hospitals’ surgical units. This helped
to identify the centres that could be suitable candidates
for experimental use of this technology. On the basis of
this analysis further indications were excluded as they
did not satisfy the criterion of feasibility for clinical trials,
because of small size of target population or the lack of
existing high-profile professional expertise and institutes
of excellence capable of employing and evaluating the
technology through appropriate research programmes.
Step 5: Recommendations for clinical research
Coherently with the limited knowledge that accompa-
nies immature technologies, assessment reports cannot
come to firm conclusions on the opportunity to adopt a
technology or not. They can nevertheless provide infor-
mation supporting restrain of unjustified diffusion in
clinical practice, while endorsing clinical use within an
experimental setting. Output of step five was the list of
clinical indications appropriate for Regional research
programmes. At the end of the process, the proposed
areas of research for the experimental use of the Da
Vinci robot in our Region were decided to be radical
prostatectomy, colo-rectal surgery and bariatric surgery.
A summary of the process and outputs for each one of
the 5 steps is given in Table 2.
Discussion and Conclusions
New health technologies and innovations in general
pose the problem of governance and every health service
or organization has experienced the disappointment of
having innovations introduced and diffused without
being able to rely on sufficient information. The pro-
blem is particularly felt with immature technologies
which invariably elicit enthusiasm, competition and
desire to pioneer.
The unplanned spread of use of technologies makes
decisions on coverage compelling before formal pro-
cesses of approvals have been completed. In these situa-
tions withdrawal or cessation of services might prove
difficult, as well as unpopular, and tying adoption poli-
cies to the development and acquisition of scientific evi-
dence on the technology’s clinical impact might be a
good way to manage momentum.
During a research project involving the evaluation of a
costly and emerging health technology (the surgical Da
Vinci robot) we developed and piloted a method that
specifically dealt with health innovations equipped with
an incomplete body of empirical knowledge. The main
assumption of the described method is that the intro-
duction of emerging health technologies into health ser-
vices and organisations ought to be related to long term
strategies of research and development and to the capa-
city of the services and organizations to carry out clini-
cal and health research [14]. The proposed method is
thus a formal process that defines experimental use of a
technology within a health system and that, by putting
the technology on “probation” for a given time, tries to
control its unplanned spread and use.
While the Regional Health Authority issued an official
notice that stopped further acquisitions of Da Vinci
robots, no reimbursement restrictions were made for
the use of the existing ones. One of the objectives of the
evaluation was therefore to agree on the clinical indica-
tions for which the robot should not be used and, as a
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like cholicystectomy, were suspended by hospitals and
surgeons.
The recommendations for research, final output of
the five-step process, did not involve an economic eva-
luation. Our method cannot compete with the more
sophisticated approaches that put the cost of research
in relation to the value of the benefits gained should
the technology prove effective [15,16]. Cost-effective-
ness and Value of Perfect Information analyses were
beyond the scope of the mandate as a comparison
between investments on different technologies was not
required [17].
A much less ambitious objective was to agree on a list
of clinical indications for which a case for promising
clinical returns could be put forward and for the evalua-
tion of which the local context should take
responsibility.
Off-shoot of this work has been the submission of a
proposal, by a group of local surgeons, for two multi-
centre clinical trials aimed at comparing clinical effec-
tiveness of robotic surgery versus laparoscopic surgery
in patients treated surgically for colo-rectal cancer and
prostate cancer.
Strengths
We believe that the strength of the method we are pro-
posing lies in its relying on scientific literature, no mat-
ter how scanty and inadequate. We took this as a
starting point to assess what has been studied so far,
what needs to be researched and the most appropriate
time for the Health Service to take direct responsibility
for the further research needed. In this approach
uncertainty is not taken to be a homogeneous state of
affairs, but is ranked according to varying levels in order
to define and choose the tolerable level of uncertainty
for engaging in the furthering of knowledge.
An additional strength of this method we believe to be
the role of the experts. When developing clinical prac-
tice guidelines experts’ opinions are combined with
scientific evidence and used to grade certainty or confi-
dence that “the desirable effects of intervention will out-
weigh the undesirable effects” [18]. When evaluating
emerging technologies panel members are asked to
grade uncertainty and state how close or far current
research is to answering their own most relevant ques-
tions. The outcome of this appraisal is obviously not to
recommend a clinical course of action, but to chart a
research course of action.
Limitations
In developing this methodology we did not address the
issue of prioritisation of assessment and did not attempt
to develop criteria to decide whether or not an emerging
technology is worthy of such an evaluation process.
Given the quantity of stimuli and proposals for innova-
tions competing for attention, a prioritisation method
needs to be developed, possibly based on preliminary
background information and on criteria suitable for scal-
ing probability of uncontrolled spread.
Our report contained only rudimental analysis of costs.
As no cost-benefit, cost-opportunity or cost-effectiveness
analyses were carried out, the method used did not
address economic evaluation of possible research returns.
Nevertheless the research areas of top clinical priority
could be further evaluated and ranked in this way.
Table 2 Process of Evaluation of Immature Technology: output of the 5 steps
Step Process Output
Step
1
- Technical description of the technology - Evidence profile
- Definition of relevant outcomes and grading of studies
- Identification of “critical outcome” setting the boundary for the acceptable maximum risk
Step
2
- Systematic review of literature - Uncertainty profile
- Analysis of quantity and quality of published research results by clinical indication for each outcome
Step
3
- Application of exclusion criteria: - List of excluded clinical
applications
a) cut off-line above which level of uncertainty is considered too high to carry out research
programmes;
b) outcomes considered of insufficient clinical value
Step
4
- Production of reports on: - Context mapping
a) data on volumes of activity and size of potential population target
b) distribution of organisational excellence and professional expertise
Step
5
- Selection of clinical indications with promising clinical returns and reflecting local expertise and
activity
- Recommendations for research
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cess could be given by the panels’ definition of the
important outcomes and the cut-off line for the accepta-
ble risk, but we believe this limit is mitigated by the
explicitness of the process and the clinical rationale on
which it is based.
Limits related to the weight of the characteristics of
the context are on the other hand inherent in the speci-
ficity of policy decisions and the method aims at setting
common criteria for selecting relevant issues of the
context.
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